--12-31falseQ20001076930UnlimitedUnlimitedP1Yhttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherAccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrentP0Yseven year00010769302023-01-012023-06-300001076930us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300001076930us-gaap:FairValueInputsLevel3Member2022-12-310001076930novt:RestOfEuropeMember2023-04-012023-06-3000010769302023-06-300001076930novt:EquityIncentivePlanTwentyTenMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2023-06-300001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-010001076930us-gaap:ResearchAndDevelopmentExpenseMember2022-04-022022-07-010001076930us-gaap:TrademarksAndTradeNamesMember2022-12-310001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-07-0100010769302022-12-310001076930us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001076930us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMember2022-01-012022-07-010001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2023-01-012023-06-300001076930novt:UnallocatedCorporateAndSharedServicesMembernovt:FiscalYearTwentyTwentyTwoMember2023-04-012023-06-300001076930srt:MinimumMemberus-gaap:WarrantyObligationsMember2023-01-012023-06-300001076930novt:FiscalYearTwentyTwentyTwoMembernovt:PrecisionMedicineAndManufacturingMember2023-04-012023-06-300001076930us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001076930us-gaap:AccountingStandardsUpdate201409Member2023-06-300001076930us-gaap:CorporateNonSegmentMember2023-01-012023-06-300001076930us-gaap:RevolvingCreditFacilityMember2023-06-300001076930us-gaap:CorporateNonSegmentMember2023-04-012023-06-300001076930us-gaap:ForeignExchangeForwardMember2023-06-300001076930novt:RobertJBuckleyMember2023-01-012023-06-300001076930us-gaap:OperatingSegmentsMembernovt:RoboticsAndAutomationMember2022-01-012022-07-010001076930novt:MedicalMember2022-04-022022-07-010001076930novt:FiscalYearTwentyTwentyMembernovt:PrecisionMedicineAndManufacturingMember2022-01-012022-07-010001076930us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300001076930us-gaap:RetainedEarningsMember2022-12-310001076930novt:AttainmentBasedPsusMembernovt:EquityIncentivePlanTwentyTenMembersrt:MaximumMember2023-01-012023-06-300001076930us-gaap:RetainedEarningsMember2023-01-012023-06-300001076930novt:RobertJBuckleyMember2023-06-300001076930novt:SeveranceAndOtherChargesMembernovt:FiscalYearTwentyTwentyTwoMember2023-01-012023-06-300001076930novt:ARGESGmbHMember2021-12-310001076930novt:ARGESGmbHMember2022-03-012022-03-310001076930us-gaap:RevolvingCreditFacilityMember2022-12-310001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-07-010001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:PerformanceSharesMember2022-12-310001076930us-gaap:CostOfSalesMember2022-01-012022-07-010001076930us-gaap:FacilityClosingMember2023-06-300001076930novt:MedicalMember2023-04-012023-06-300001076930novt:EquityIncentivePlanTwentyTenMembersrt:MinimumMembernovt:HybridPsusMember2023-01-012023-06-300001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-012023-06-300001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001076930us-gaap:CostOfSalesMember2022-04-022022-07-010001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-06-3000010769302021-05-012021-05-310001076930novt:FiscalYearTwentyTwentyMember2023-04-012023-06-300001076930us-gaap:OtherRestructuringMember2023-01-012023-06-300001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001076930novt:AdvancedIndustrialMember2023-01-012023-06-300001076930novt:OtherCountriesMember2022-01-012022-07-010001076930novt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930srt:MaximumMembernovt:EquityIncentivePlanTwentyTenMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-06-300001076930us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMember2023-04-012023-06-300001076930novt:ARGESGmbHMember2019-07-310001076930us-gaap:RetainedEarningsMember2023-04-012023-06-300001076930us-gaap:OperatingSegmentsMembernovt:RoboticsAndAutomationMember2022-04-022022-07-010001076930us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMember2022-04-022022-07-010001076930us-gaap:RetainedEarningsMember2023-06-300001076930novt:FiscalYearTwentyTwentyMember2022-01-012022-07-010001076930novt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-310001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:TermLoanMember2023-01-012023-06-300001076930novt:FiscalYearTwentyTwentyTwoMembernovt:MedicalSolutionsMember2023-01-012023-06-300001076930novt:RoboticsAndAutomationMember2023-06-3000010769302023-04-012023-06-300001076930us-gaap:CommonStockMember2021-12-310001076930novt:ARGESGmbHMember2020-12-310001076930novt:EmployeeRelatedMember2022-12-310001076930novt:TermLoanMember2022-12-310001076930novt:ARGESGmbHMember2022-12-310001076930novt:FiscalYearTwentyTwentyMembernovt:MedicalSolutionsMember2022-01-012022-07-010001076930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:MatthijsGlastraMember2023-01-012023-06-3000010769302022-04-010001076930novt:UnallocatedCorporateAndSharedServicesMembernovt:FiscalYearTwentyTwentyTwoMember2023-01-012023-06-300001076930country:DE2023-01-012023-06-300001076930novt:RestOfEuropeMember2023-01-012023-06-300001076930us-gaap:CommonStockMember2022-04-022022-07-010001076930novt:TermLoanMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2019-12-310001076930us-gaap:CostOfSalesMember2023-04-012023-06-300001076930us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-07-010001076930srt:MinimumMember2023-01-012023-06-300001076930novt:EquityIncentivePlanTwentyTenMember2023-01-012023-06-300001076930us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-06-300001076930srt:MaximumMembernovt:EquityIncentivePlanTwentyTenMembernovt:HybridPsusMember2023-01-012023-06-300001076930us-gaap:RetainedEarningsMember2022-07-010001076930country:CN2022-04-022022-07-010001076930novt:FiscalYearTwentyTwentyMembernovt:RoboticsAndAutomationMember2022-04-022022-07-0100010769302022-07-010001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2023-02-012023-02-280001076930us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930novt:RoboticsAndAutomationMember2022-12-310001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100010769302021-05-310001076930us-gaap:AdditionalPaidInCapitalMember2022-04-010001076930novt:FifthAmendmentCreditFacilitiesMember2019-12-302019-12-310001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:TermLoanMember2019-12-302019-12-310001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001076930srt:MaximumMember2023-01-012023-06-300001076930us-gaap:RetainedEarningsMember2021-12-310001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2022-01-012022-07-010001076930novt:FiscalYearTwentyTwentyTwoMember2023-06-300001076930srt:MaximumMembernovt:FiscalYearTwentyTwentyMember2023-06-300001076930novt:RestOfAsiaPacificMember2022-04-022022-07-010001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:FourthAmendmentRevolvingCreditFacilityMember2021-10-050001076930country:CN2023-01-012023-06-300001076930us-gaap:WarrantyObligationsMember2023-01-012023-06-300001076930us-gaap:FacilityClosingMember2022-12-310001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:DirectorMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2023-01-012023-06-300001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2023-06-300001076930us-gaap:FairValueInputsLevel3Member2023-01-012023-06-300001076930us-gaap:AdditionalPaidInCapitalMember2021-12-310001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2022-01-012022-07-010001076930us-gaap:CommonStockMember2023-06-300001076930novt:FiscalYearTwentyTwentyTwoMembernovt:PrecisionMedicineAndManufacturingMember2023-01-012023-06-300001076930novt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:MatthijsGlastraMember2023-06-300001076930novt:HybridPsusMember2023-06-300001076930us-gaap:FairValueInputsLevel2Membernovt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930novt:FiscalYearTwentyTwentyMember2023-01-012023-06-300001076930srt:MinimumMembernovt:FiscalYearTwentyTwentyTwoMember2023-06-300001076930novt:SeveranceAndOtherChargesMembernovt:FiscalYearTwentyTwentyTwoMember2023-04-012023-06-300001076930srt:MaximumMembernovt:EquityIncentivePlanTwentyTenMembernovt:MarketBasedPsusMember2023-01-012023-06-300001076930us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-06-300001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2023-04-012023-06-300001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2022-01-012022-07-010001076930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-3100010769302022-04-022022-07-010001076930us-gaap:RetainedEarningsMember2022-04-022022-07-010001076930us-gaap:CommonStockMember2022-07-010001076930novt:FiscalYearTwentyTwentyMember2023-06-300001076930us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930novt:ARGESGmbHMember2023-01-012023-06-300001076930srt:MaximumMembernovt:ProfessionalServicesMember2023-01-012023-06-300001076930novt:FiscalYearTwentyTwentyMembernovt:RoboticsAndAutomationMember2023-01-012023-06-300001076930srt:MaximumMembernovt:ProfessionalServicesMember2022-01-012022-07-010001076930us-gaap:CommonStockMember2022-12-310001076930novt:FiscalYearTwentyTwentyTwoMember2023-01-012023-06-300001076930us-gaap:OperatingSegmentsMembernovt:RoboticsAndAutomationMember2023-01-012023-06-300001076930us-gaap:RetainedEarningsMember2022-04-010001076930novt:EmployeeRelatedMember2023-01-012023-06-300001076930us-gaap:ForeignExchangeForwardMemberus-gaap:ForeignCurrencyGainLossMember2023-01-012023-06-300001076930novt:PerformanceBasedRestrictedStockUnitsMember2022-07-010001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001076930srt:MinimumMember2023-06-300001076930us-gaap:CommonStockMember2023-03-310001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2023-01-012023-06-300001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2023-01-012023-06-300001076930novt:FiscalYearTwentyTwentyMembernovt:PrecisionMedicineAndManufacturingMember2023-01-012023-06-300001076930novt:EquityIncentivePlanTwentyTenMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2023-01-012023-06-300001076930us-gaap:RetainedEarningsMember2023-03-310001076930srt:MaximumMemberus-gaap:LandMember2023-01-012023-06-300001076930novt:FiscalYearTwentyTwentyTwoMember2023-04-012023-06-300001076930novt:AdvancedIndustrialMember2023-04-012023-06-300001076930us-gaap:TechnologyBasedIntangibleAssetsMember2022-12-310001076930novt:TermLoanMember2023-06-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2023-01-012023-06-300001076930novt:FiscalYearTwentyTwentyMembernovt:PrecisionMedicineAndManufacturingMember2022-04-022022-07-010001076930us-gaap:AdditionalPaidInCapitalMember2022-07-010001076930us-gaap:CommonStockMember2023-01-012023-06-300001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2023-06-300001076930novt:MedicalMember2022-01-012022-07-010001076930novt:TwoThousandTwentyCommonStockRepurchasePlanMember2020-02-290001076930novt:FiscalYearTwentyTwentyMembernovt:RoboticsAndAutomationMember2022-01-012022-07-010001076930novt:MedicalSolutionsMember2022-12-310001076930us-gaap:CostOfSalesMember2023-01-012023-06-300001076930novt:EquityIncentivePlanTwentyTenMembernovt:DeferredStockUnitsMember2022-12-310001076930us-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930novt:OtherCountriesMember2023-04-012023-06-300001076930country:CN2022-01-012022-07-010001076930us-gaap:OtherRestructuringMember2022-12-310001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:PerformanceSharesMember2023-06-300001076930novt:OtherCountriesMember2022-04-022022-07-010001076930us-gaap:FairValueInputsLevel2Memberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:RestOfEuropeMember2022-01-012022-07-010001076930us-gaap:OperatingSegmentsMembernovt:PrecisionMedicineAndManufacturingMember2022-04-022022-07-010001076930novt:RestOfAsiaPacificMember2023-04-012023-06-300001076930novt:TermLoanAndRevolvingCreditFacilityMember2023-06-300001076930us-gaap:FacilityClosingMember2023-01-012023-06-300001076930us-gaap:FairValueInputsLevel2Membernovt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:FiscalYearTwentyTwentyMembernovt:EmployeeSeveranceAndOtherCostsMember2023-04-012023-06-300001076930novt:EquityIncentivePlanTwentyTenMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2022-12-3100010769302022-01-012022-12-310001076930country:US2023-01-012023-06-300001076930us-gaap:CommonStockMember2023-04-012023-06-300001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-06-3000010769302022-01-012022-07-010001076930novt:FiscalYearTwentyTwentyTwoMembernovt:RoboticsAndAutomationMember2023-01-012023-06-300001076930novt:RestOfAsiaPacificMember2022-01-012022-07-010001076930novt:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-12-302019-12-3100010769302023-03-310001076930novt:PerformanceBasedRestrictedStockUnitsMember2023-06-300001076930novt:OtherCountriesMember2023-01-012023-06-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:FifthAmendmentRevolvingCreditFacilityMember2022-03-102022-03-100001076930novt:MedicalSolutionsMember2023-06-300001076930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:AdvancedIndustrialMember2022-04-022022-07-010001076930novt:ProfessionalAndConsultingFeesMember2023-01-012023-06-300001076930us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001076930novt:AdvancedIndustrialMember2022-01-012022-07-010001076930us-gaap:OperatingSegmentsMembernovt:MedicalSolutionsMember2022-04-022022-07-010001076930country:US2022-04-022022-07-010001076930novt:RestOfAsiaPacificMember2023-01-012023-06-300001076930us-gaap:AdditionalPaidInCapitalMember2023-06-300001076930novt:FiscalYearTwentyTwentyMembernovt:PrecisionMedicineAndManufacturingMember2023-04-012023-06-300001076930us-gaap:OperatingSegmentsMembernovt:MedicalSolutionsMember2023-04-012023-06-300001076930us-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930us-gaap:OtherRestructuringMember2023-06-300001076930novt:AttainmentBasedPsusMembernovt:EquityIncentivePlanTwentyTenMembersrt:MinimumMember2023-01-012023-06-300001076930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-12-3100010769302023-08-010001076930novt:FiscalYearTwentyTwentyMembernovt:MedicalSolutionsMember2022-04-022022-07-010001076930us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:FifthAmendmentRevolvingCreditFacilityMember2022-03-100001076930novt:MedicalMember2023-01-012023-06-300001076930novt:EquityIncentivePlanTwentyTenMembernovt:DeferredStockUnitsMember2023-06-300001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2022-12-310001076930us-gaap:AdditionalPaidInCapitalMember2022-01-012022-07-010001076930country:DE2022-01-012022-07-010001076930us-gaap:CommonStockMember2022-04-010001076930novt:ProfessionalAndConsultingFeesMember2022-01-012022-07-010001076930novt:RestOfEuropeMember2022-04-022022-07-010001076930us-gaap:AccountingStandardsUpdate201409Member2023-01-012023-06-300001076930us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930us-gaap:CustomerRelationshipsMember2023-06-300001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001076930us-gaap:EmployeeStockOptionMember2023-01-012023-06-300001076930us-gaap:OperatingSegmentsMembernovt:MedicalSolutionsMember2023-01-012023-06-300001076930us-gaap:ForeignExchangeForwardMember2022-12-310001076930us-gaap:OperatingSegmentsMembernovt:MedicalSolutionsMember2022-01-012022-07-010001076930novt:FiscalYearTwentyTwentyTwoMembernovt:RoboticsAndAutomationMember2023-04-012023-06-300001076930us-gaap:CorporateNonSegmentMember2022-01-012022-07-010001076930us-gaap:TechnologyBasedIntangibleAssetsMember2023-06-300001076930us-gaap:CommonStockMember2022-01-012022-07-010001076930us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-04-022022-07-010001076930us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2023-04-012023-06-300001076930country:DE2023-04-012023-06-300001076930novt:FiscalYearTwentyTwentyMembernovt:EmployeeSeveranceAndOtherCostsMember2023-01-012023-06-300001076930country:CN2023-04-012023-06-300001076930srt:MaximumMembernovt:FiscalYearTwentyTwentyTwoMember2023-06-300001076930us-gaap:TrademarksAndTradeNamesMember2023-06-300001076930novt:TermLoanAndRevolvingCreditFacilityMember2022-12-310001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930us-gaap:AdditionalPaidInCapitalMember2023-03-310001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930country:US2023-04-012023-06-300001076930novt:ARGESGmbHMember2021-03-012021-03-310001076930novt:FiscalYearTwentyTwentyTwoMembernovt:MedicalSolutionsMember2023-04-012023-06-300001076930novt:EmployeeRelatedMember2023-06-300001076930srt:MinimumMembernovt:FiscalYearTwentyTwentyMember2023-06-300001076930us-gaap:AccountingStandardsUpdate201409Member2022-12-3100010769302021-12-310001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:PerformanceSharesMember2023-01-012023-06-300001076930novt:ProfessionalAndConsultingFeesMember2022-04-022022-07-010001076930us-gaap:CanadaRevenueAgencyMembercountry:CA2022-04-022022-07-010001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-022022-07-010001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-010001076930us-gaap:CorporateNonSegmentMember2022-04-022022-07-010001076930novt:TermLoanMembernovt:ThirdAmendedAndRestatedCreditAgreementMember2020-03-012020-03-310001076930us-gaap:OperatingExpenseMember2023-06-300001076930us-gaap:CostOfSalesMember2023-06-300001076930us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930country:DE2022-04-022022-07-010001076930us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001076930us-gaap:RetainedEarningsMember2022-01-012022-07-010001076930country:US2022-01-012022-07-010001076930us-gaap:ForeignExchangeForwardMember2023-01-012023-06-300001076930novt:EpsAndApplicableRelativeTsrPerformanceConditionsMember2023-01-012023-06-300001076930novt:ProfessionalAndConsultingFeesMember2023-04-012023-06-300001076930us-gaap:AdditionalPaidInCapitalMember2022-04-022022-07-010001076930us-gaap:CustomerRelationshipsMember2022-12-310001076930srt:MaximumMemberus-gaap:ForeignExchangeForwardMember2022-01-012022-12-310001076930srt:MaximumMemberus-gaap:WarrantyObligationsMember2023-01-012023-06-300001076930srt:MaximumMember2023-06-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMembernovt:FirstAmendmentRevolvingCreditFacilityMember2020-03-270001076930novt:FiscalYearTwentyTwentyMembernovt:RoboticsAndAutomationMember2023-04-012023-06-300001076930novt:PrecisionMedicineAndManufacturingMember2023-06-300001076930us-gaap:AdditionalPaidInCapitalMember2022-12-310001076930us-gaap:OperatingSegmentsMembernovt:RoboticsAndAutomationMember2023-04-012023-06-300001076930novt:ThirdAmendedAndRestatedCreditAgreementMemberus-gaap:RevolvingCreditFacilityMember2019-12-310001076930novt:EquityIncentivePlanTwentyTenMembersrt:MinimumMembernovt:MarketBasedPsusMember2023-01-012023-06-300001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:SellingGeneralAndAdministrativeExpensesMembersrt:DirectorMembernovt:RestrictedStockUnitsAndDeferredStockUnitsMember2022-01-012022-07-010001076930novt:HybridPsusMember2023-01-012023-06-300001076930novt:AccruedExpensesAndOtherCurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-06-300001076930us-gaap:FairValueInputsLevel3Member2023-06-300001076930novt:FiscalYearTwentyTwentyMember2022-04-022022-07-010001076930us-gaap:FairValueMeasurementsRecurringMember2022-12-310001076930novt:EquityIncentivePlanTwentyTenMemberus-gaap:EmployeeStockOptionMember2023-01-012023-06-300001076930novt:PrecisionMedicineAndManufacturingMember2022-12-31iso4217:EURiso4217:USDxbrli:sharesxbrli:purenovt:EndMarketxbrli:sharesnovt:Segmentiso4217:USD

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

Or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File No.: 001-35083

NOVANTA INC.

(Exact name of registrant as specified in its charter)

New Brunswick, Canada

98-0110412

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

 

125 Middlesex Turnpike, Bedford, Massachusetts, USA

01730

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (781) 266-5700

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common shares, no par value

 

NOVT

 

The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

 

Large accelerated filer

Accelerated filer

 

 

Non-accelerated filer

Smaller reporting company

 

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of August 1, 2023, there were 35,808,329 of the Registrant’s common shares, no par value, issued and outstanding.

 

 


 

NOVANTA INC.

TABLE OF CONTENTS

Item No.

 

Page
No.

 

 

PART I — FINANCIAL INFORMATION

1

 

 

 

ITEM 1.

FINANCIAL STATEMENTS

1

 

 

 

CONSOLIDATED BALANCE SHEETS (unaudited)

1

 

 

 

CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)

2

 

 

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited)

3

 

 

 

 

 

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited)

 

4

 

 

 

 

 

CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

5

 

 

 

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited)

6

 

 

 

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

26

 

 

 

ITEM 3.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

38

 

 

 

ITEM 4.

CONTROLS AND PROCEDURES

38

 

 

PART II — OTHER INFORMATION

39

 

 

 

ITEM 1.

LEGAL PROCEEDINGS

39

 

 

 

ITEM 1A.

RISK FACTORS

39

 

 

 

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS, AND ISSUER PURCHASES OF EQUITY SECURITIES

39

 

 

 

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

39

 

 

 

ITEM 4.

MINE SAFETY DISCLOSURES

40

 

 

 

ITEM 5.

OTHER INFORMATION

40

 

 

 

ITEM 6.

EXHIBITS

40

 

 

SIGNATURES

42

 

 

 

 


 

 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

NOVANTA INC.

CONSOLIDATED BALANCE SHEETS

(In thousands of U.S. dollars or shares)

(Unaudited)

 

June 30,

 

 

December 31,

 

 

2023

 

 

2022

 

ASSETS

 

 

 

 

 

Current assets

 

 

 

 

 

Cash and cash equivalents

$

91,330

 

 

$

100,105

 

Accounts receivable, net of allowance of $1,316 and $995, respectively

 

144,837

 

 

 

137,697

 

Inventories

 

162,904

 

 

 

167,997

 

Prepaid income taxes and income taxes receivable

 

3,144

 

 

 

1,508

 

Prepaid expenses and other current assets

 

12,128

 

 

 

13,212

 

Total current assets

 

414,343

 

 

 

420,519

 

Property, plant and equipment, net

 

103,801

 

 

 

103,186

 

Operating lease assets

 

43,280

 

 

 

43,317

 

Deferred tax assets

 

21,215

 

 

 

15,113

 

Other assets

 

5,718

 

 

 

4,414

 

Intangible assets, net

 

160,956

 

 

 

175,766

 

Goodwill

 

483,409

 

 

 

478,897

 

Total assets

$

1,232,722

 

 

$

1,241,212

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

Current liabilities

 

 

 

 

 

Current portion of long-term debt

$

4,906

 

 

$

4,800

 

Accounts payable

 

64,653

 

 

 

75,225

 

Income taxes payable

 

6,592

 

 

 

13,660

 

Current portion of operating lease liabilities

 

7,881

 

 

 

7,793

 

Accrued expenses and other current liabilities

 

51,946

 

 

 

63,044

 

Total current liabilities

 

135,978

 

 

 

164,522

 

Long-term debt

 

403,586

 

 

 

430,662

 

Operating lease liabilities

 

40,729

 

 

 

40,808

 

Deferred tax liabilities

 

16,175

 

 

 

17,194

 

Income taxes payable

 

4,661

 

 

 

4,355

 

Other liabilities

 

5,563

 

 

 

6,085

 

Total liabilities

 

606,692

 

 

 

663,626

 

Commitments and contingencies (Note 14)

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

Preferred shares, no par value; Authorized shares: 7,000;
   
No shares issued and outstanding

 

 

 

 

 

Common shares, no par value; Authorized shares: unlimited;
   Issued and outstanding:
35,808 and 35,711, respectively

 

423,856

 

 

 

423,856

 

Additional paid-in capital

 

57,488

 

 

 

55,155

 

Retained earnings

 

169,728

 

 

 

130,584

 

Accumulated other comprehensive loss

 

(25,042

)

 

 

(32,009

)

Total stockholders' equity

 

626,030

 

 

 

577,586

 

Total liabilities and stockholders’ equity

$

1,232,722

 

 

$

1,241,212

 

 

The accompanying notes are an integral part of these consolidated financial statements.

1


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands of U.S. dollars or shares, except per share amounts)

(Unaudited)

 

Three Months Ended

 

 

Six Months Ended

 

 

June 30,

 

 

July 1,

 

 

June 30,

 

 

July 1,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Revenue

$

229,464

 

 

$

215,356

 

 

$

448,590

 

 

$

419,572

 

Cost of revenue

 

125,341

 

 

 

120,111

 

 

 

246,839

 

 

 

234,051

 

Gross profit

 

104,123

 

 

 

95,245

 

 

 

201,751

 

 

 

185,521

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

Research and development and engineering

 

23,380

 

 

 

21,588

 

 

 

46,208

 

 

 

42,517

 

Selling, general and administrative

 

42,187

 

 

 

40,538

 

 

 

83,110

 

 

 

79,890

 

Amortization of purchased intangible assets

 

5,124

 

 

 

7,173

 

 

 

10,213

 

 

 

14,515

 

Restructuring, acquisition, and related costs

 

1,234

 

 

 

2,655

 

 

 

3,710

 

 

 

1,025

 

Total operating expenses

 

71,925

 

 

 

71,954

 

 

 

143,241

 

 

 

137,947

 

Operating income

 

32,198

 

 

 

23,291

 

 

 

58,510

 

 

 

47,574

 

Interest income (expense), net

 

(6,810

)

 

 

(2,757

)

 

 

(13,142

)

 

 

(5,866

)

Foreign exchange transaction gains (losses), net

 

74

 

 

 

152

 

 

 

(3

)

 

 

221

 

Other income (expense), net

 

(191

)

 

 

68

 

 

 

(357

)

 

 

(477

)

Income before income taxes

 

25,271

 

 

 

20,754

 

 

 

45,008

 

 

 

41,452

 

Income tax provision (benefit)

 

4,392

 

 

 

3,275

 

 

 

5,864

 

 

 

5,153

 

Consolidated net income

$

20,879

 

 

$

17,479

 

 

$

39,144

 

 

$

36,299

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per common share (Note 4):

 

 

 

 

 

 

 

 

 

 

 

Basic

$

0.58

 

 

$

0.49

 

 

$

1.09

 

 

$

1.02

 

Diluted

$

0.58

 

 

$

0.49

 

 

$

1.09

 

 

$

1.01

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average common shares outstanding—basic

 

35,851

 

 

 

35,609

 

 

 

35,830

 

 

 

35,573

 

Weighted average common shares outstanding—diluted

 

36,032

 

 

 

35,933

 

 

 

36,015

 

 

 

35,857

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

2


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands of U.S. dollars)

(Unaudited)

 

Three Months Ended

 

 

Six Months Ended

 

 

June 30,

 

 

July 1,

 

 

June 30,

 

 

July 1,

 

 

2023

 

 

2022

 

 

2023

 

 

2022

 

Consolidated net income

$

20,879

 

 

$

17,479

 

 

$

39,144

 

 

$

36,299

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

Foreign currency translation adjustments, net of tax (1)

 

1,577

 

 

 

(13,927

)

 

 

6,807

 

 

 

(18,699

)

Pension liability adjustments, net of tax (2)

 

89

 

 

 

587

 

 

 

160

 

 

 

900

 

Total other comprehensive income (loss)

 

1,666

 

 

 

(13,340

)

 

 

6,967

 

 

 

(17,799

)

Total consolidated comprehensive income

$

22,545

 

 

$

4,139

 

 

$

46,111

 

 

$

18,500

 

 

(1)
The tax effect on this component of comprehensive income (loss) was nominal for all periods presented.
(2)
The tax effect on this component of comprehensive income (loss) was nominal for all periods presented. See Note 3 to the Consolidated Financial Statements for the total amount of pension liability adjustments reclassified out of accumulated other comprehensive income (loss).

The accompanying notes are an integral part of these consolidated financial statements.

 

3


 

NOVANTA INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(In thousands of U.S. dollars or shares)

(Unaudited)

 

 

Common Shares

 

 

Additional Paid-In

 

 

Retained

 

 

Accumulated Other

 

 

 

 

 

# of Shares

 

 

Amount

 

 

Capital

 

 

Earnings

 

 

Comprehensive Loss

 

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended June 30, 2023

 

Balance at March 31, 2023

 

35,802

 

 

$

423,856

 

 

$

52,020

 

 

$

148,849

 

 

$

(26,708

)

 

$

598,017

 

Consolidated net income

 

 

 

 

 

 

 

 

 

 

20,879

 

 

 

 

 

 

20,879

 

Common shares issued under stock plans

 

9

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(3

)

 

 

 

 

 

(407

)

 

 

 

 

 

 

 

 

(407

)

Share-based compensation

 

 

 

 

 

 

 

5,875

 

 

 

 

 

 

 

 

 

5,875

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

1,666

 

 

 

1,666

 

Balance at June 30, 2023

 

35,808

 

 

$

423,856

 

 

$

57,488

 

 

$

169,728

 

 

$

(25,042

)

 

$

626,030

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended June 30, 2023

 

Balance at December 31, 2022

 

35,711

 

 

$

423,856

 

 

$

55,155

 

 

$

130,584

 

 

$

(32,009

)

 

$

577,586

 

Consolidated net income

 

 

 

 

 

 

 

 

 

 

39,144

 

 

 

 

 

 

39,144

 

Common shares issued under stock plans

 

164

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(67

)

 

 

 

 

 

(10,008

)

 

 

 

 

 

 

 

 

(10,008

)

Share-based compensation

 

 

 

 

 

 

 

12,341

 

 

 

 

 

 

 

 

 

12,341

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

6,967

 

 

 

6,967

 

Balance at June 30, 2023

 

35,808

 

 

$

423,856

 

 

$

57,488

 

 

$

169,728

 

 

$

(25,042

)

 

$

626,030

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended July 1, 2022

 

Balance at April 1, 2022

 

35,684

 

 

$

423,856

 

 

$

52,809

 

 

$

75,353

 

 

$

(17,325

)

 

$

534,693

 

Consolidated net income

 

 

 

 

 

 

 

 

 

 

17,479

 

 

 

 

 

 

17,479

 

Common shares issued under stock plans

 

37

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Common shares withheld for taxes on vested stock awards

 

(14

)

 

 

 

 

 

(1,744

)

 

 

 

 

 

 

 

 

(1,744

)

Repurchases of common shares

 

(84

)

 

 

 

 

 

(10,000

)

 

 

 

 

 

 

 

 

(10,000

)

Share-based compensation

 

 

 

 

 

 

 

5,081

 

 

 

 

 

 

 

 

 

5,081

 

Other comprehensive income (loss), net of tax

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,340

)

 

 

(13,340

)

Balance at July 1, 2022

 

35,623

 

 

$

423,856

 

 

$

46,146

 

 

$

92,832

 

 

$

(30,665

)

 

$

532,169

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six Months Ended July 1, 2022

 

Balance at December 31, 2021

 

35,601

 

 

$

423,856

 

 

$

53,768

 

 

$

56,533

 

 

$

(12,866

)

 

$

521,291

 

Consolidated net income

 

 

 

 

 

 

 

 

 

 

36,299